<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694642</url>
  </required_header>
  <id_info>
    <org_study_id>progenitorCD133</org_study_id>
    <nct_id>NCT00694642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis</brief_title>
  <acronym>PROGENITOR</acronym>
  <official_title>Safety and Efficacy of Transendocardial Injection of Autologous Endothelial Progenitor Cell CD 133 for Therapeutics Angiogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pilar Jimenez Quevedo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Mutua Madrileña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether transendocardial injections of autologous
      endothelial progenitor cells CD 133 is safe and feasible in patients with refractory angina.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROGENITOR trial is a randomized, double-blinded, multicenter controlled trial including
      patients with Canadian cardiovascular society angina classification (CCS): II-IV and ischemic
      zones by SPECT but without any option for revascularization. Primary endpoint was to assess
      the safety and feasibility of transendocardial injection of selected CD133+cells. All
      patients were treated for 4-days with granulocyte colony-stimulating factor and underwent
      apheresis. CD133+ cells were selected with CliniMacs system and were injected
      transendocardially guided by the NOGA XP system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major adverse cardiac and cerebrovascular event</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>cardiovascular death, non-fatal myocardial infarction (MI), ischemic stroke, need for revascularization or , procedure-related complications (: pericardial effusion/cardiac tamponade, vascular complications and sustained ventricular arrhythmias).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>The change in the myocardial perfusion defect at baseline versus follow-up measured by Single Photon Emission Computed Tomography (SPECT). Treadmill test, and clinical evaluation (CCS, nº angina episodes/month, nº nitroglycerin /month, Quality of life by seattle questionnaire)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Refractory Angina</condition>
  <arm_group>
    <arm_group_label>selected CD133+cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transendocardial injection of selected CD133+cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no injection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Selected CD 133+ cells</intervention_name>
    <description>Endothelial progenitor cell CD 133</description>
    <arm_group_label>selected CD133+cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional class II- IV angina on maximal medical therapy

          -  Myocardial Ischemia/viability demonstrated by a reversible perfusion defect by means
             imaging techniques

          -  Patients should not be amenable to any type of revascularization procedure
             (percutaneous or surgical)

          -  Signed informed consent

        Exclusion Criteria:

          -  Age &lt;18 years or &gt;75 years.

          -  Atrial fibrillation.

          -  LV thrombus

          -  Acute myocardial infarction in the last 3 months

          -  An LV wall thickness of &lt;8 mm at the target site for cell injection

          -  A history of malignancy in the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Jimenez-Quevedo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hostpial Clinico San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>August 4, 2013</last_update_submitted>
  <last_update_submitted_qc>August 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Pilar Jimenez Quevedo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Refractory angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

